Top

Published in:

19-07-2023 | Melanoma | Research

Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells

Authors: Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, Chantal Combredet, Soizic Dutoit, Sophie Deshayes, Virginie Dehame, Nathalie Labarrière, Delphine Fradin, Nicolas Boisgerault, Christophe Blanquart, Frédéric Tangy, Jean-François Fonteneau

Published in: Cancer Immunology, Immunotherapy | Issue 10/2023

Abstract

Antitumor virotherapy stimulates the antitumor immune response during tumor cell lysis induced by oncolytic viruses (OVs). OV can be modified to express additional transgenes that enhance their therapeutic potential. In this study, we armed the spontaneously oncolytic Schwarz strain of measles viruses (MVs) with the gene encoding the cancer/testis antigen NY-ESO-1 to obtain MVny. We compared MV and MVny oncolytic activity and ability to induce NY-ESO-1 expression in six human melanoma cell lines. After MVny infection, we measured the capacity of melanoma cells to present NY-ESO-1 peptides to CD4 + and CD8 + T cell clones specific for this antigen. We assessed the ability of MVny to induce NY-ESO-1 expression and presentation in monocyte-derived dendritic cells (DCs). Our results show that MVny and MV oncolytic activity are similar with a faster cell lysis induced by MVny. We also observed that melanoma cell lines and DC expressed the NY-ESO-1 protein after MVny infection. In addition, MVny-infected melanoma cells and DCs were able to stimulate NY-ESO-1-specific CD4 + and CD8 + T cells. Finally, MVny was able to induce DC maturation. Altogether, these results show that MVny could be an interesting candidate to stimulate NY-ESO-1-specific T cells in melanoma patients with NY-ESO-1-expressing tumor cells.

Available only for authorised users

Macedo N, Miller DM, Haq R, Kaufman HL (2020) Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 8

Achard C, Surendran A, Wedge ME et al (2018) Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31:17–24CrossRefPubMedPubMedCentral

Gauvrit A, Brandler S, Sapede-Peroz C et al (2008) Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 68:4882–4892CrossRefPubMed

Guillerme JB, Boisgerault N, Roulois D et al (2013) Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 19:1147–1158CrossRefPubMed

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146CrossRefPubMed

Meng X, Sun X, Liu Z, He Y (2021) A novel era of cancer/testis antigen in cancer immunotherapy. Int Immunopharmacol 98:107889CrossRefPubMed

Gnjatic S, Nishikawa H, Jungbluth AA et al (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1–30CrossRefPubMed

Jager E, Chen YT, Drijfhout JW et al (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270CrossRefPubMedPubMedCentral

Wang RF, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27:11–37CrossRefPubMed

10.

Thomas R, Al-Khadairi G, Roelands J et al (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947CrossRefPubMedPubMedCentral

11.

Allagui F, Achard C, Panterne C et al (2017) Modulation of the type I interferon response defines the sensitivity of human melanoma cells to oncolytic measles virus. Curr Gene Ther 16:419–428. https://doi.org/10.2174/1566523217666170102110502CrossRefPubMed

12.

Boisgerault N, Guillerme JB, Pouliquen D et al (2013) Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Res Int 2013:387362CrossRefPubMedPubMedCentral

13.

Achard C, Boisgerault N, Delaunay T et al (2015) Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget 6:44892–44904. https://doi.org/10.18632/oncotarget.6285CrossRefPubMedPubMedCentral

14.

Delaunay T, Achard C, Boisgerault N et al (2020) Frequent homozygous deletions of type i interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thoracic Oncol : Official Public Int Assoc Study of Lung Cancer 15:827–842. https://doi.org/10.1016/j.jtho.2019.12.128CrossRef

15.

Msaouel P, Opyrchal M, Dispenzieri A et al (2018) Clinical trials with oncolytic measles virus: current status and future prospects. Curr Cancer Drug Targets 18:177–187CrossRefPubMedPubMedCentral

16.

Backhaus PS, Veinalde R, Hartmann L, et al (2019) Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 Agonists. Viruses 11

17.

Speck T, Heidbuechel JPW, Veinalde R et al (2018) Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res 24:2128–2137CrossRefPubMed

18.

Dispenzieri A, Tong C, LaPlant B et al (2017) Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31:2791–2798CrossRefPubMedPubMedCentral

19.

Frantz PN, Barinov A, Ruffie C et al (2021) A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Nat Commun 12:6277CrossRefPubMedPubMedCentral

20.

Ramsauer K, Schwameis M, Firbas C et al (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15:519–527CrossRefPubMed

21.

Pol JG, Zhang L, Bridle BW et al (2014) Maraba virus as a potent oncolytic vaccine vector. Mol Ther 22:420–429. https://doi.org/10.1038/mt.2013.249CrossRefPubMed

22.

Busch E, Kubon KD, Mayer JKM et al (2020) Measles vaccines designed for enhanced CD8+ T cell activation. Viruses 12:242. https://doi.org/10.3390/v12020242CrossRefPubMedPubMedCentral

23.

Fonteneau JF, Larsson M, Somersan S et al (2001) Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258:111–126CrossRefPubMed

24.

Roulois D, Vignard V, Gueugnon F et al (2011) Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells. Eur Respir J 38:1117–1126CrossRefPubMed

25.

Benlalam H, Labarrière N, Linard B et al (2001) Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 31:2007–2015. https://doi.org/10.1002/1521-4141(200107)31:7%3c2007::aid-immu2007%3e3.0.co;2-sCrossRefPubMed

26.

Coulais D, Panterne C, Fonteneau JF, Gregoire M (2012) Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads. Cytotherapy 14:887–896CrossRefPubMed

27.

Combredet C, Labrousse V, Mollet L et al (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77:11546–11554CrossRefPubMedPubMedCentral

28.

Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682CrossRefPubMed

29.

Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622. https://doi.org/10.1373/clinchem.2008.112797CrossRefPubMed

30.

Ohgimoto K, Ohgimoto S, Ihara T et al (2007) Difference in production of infectious wild-type measles and vaccine viruses in monocyte-derived dendritic cells. Virus Res 123:1–8. https://doi.org/10.1016/j.virusres.2006.07.006CrossRefPubMed

31.

Sanchez David RY, Combredet C, Sismeiro O et al (2016) Comparative analysis of viral RNA signatures on different RIG-I-like receptors. eLife 5: 11275

32.

Mura M, Combredet C, Najburg V et al (2017) Nonencapsidated 5′ copy-back defective interfering genomes produced by recombinant measles viruses are recognized by RIG-I and LGP2 but not MDA5. J Virol 91:e00643-e717. https://doi.org/10.1128/JVI.00643-17CrossRefPubMedPubMedCentral

33.

Donnelly OG, Errington-Mais F, Steele L et al (2011) Measles virus causes immunogenic cell death in human melanoma. Gene Ther

34.

Fonteneau JF, Brilot F, Munz C, Gannage M (2016) The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. J Immunol 196:64–71CrossRefPubMed

35.

Delaunay T, Violland M, Boisgerault N et al (2018) Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology 7:e1407897. https://doi.org/10.1080/2162402x.2017.1407897CrossRefPubMed

36.

Velazquez EF, Jungbluth AA, Yancovitz M et al (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)–correlation with prognostic factors. Cancer Immun 7:11PubMedPubMedCentral

37.

Barrow C, Browning J, MacGregor D et al (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764–771CrossRefPubMed

38.

Goydos JS, Patel M, Shih W (2001) NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98:76–80CrossRefPubMed

39.

Hunder NN, Wallen H, Cao J et al (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698–2703CrossRefPubMedPubMedCentral

40.

Robbins PF, Kassim SH, Tran TL et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21:1019–1027CrossRefPubMed

Title: Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells
Authors: Marion Grard
Mohamed Idjellidaine
Atousa Arbabian
Camille Chatelain
Laurine Berland
Chantal Combredet
Soizic Dutoit
Sophie Deshayes
Virginie Dehame
Nathalie Labarrière
Delphine Fradin
Nicolas Boisgerault
Christophe Blanquart
Frédéric Tangy
Jean-François Fonteneau
Publication date: 19-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Melanoma
Melanoma
Published in: Cancer Immunology, Immunotherapy / Issue 10/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-023-03486-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2023

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy

Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer